Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · IEX Real-Time Price · USD
27.51
+0.49 (1.81%)
At close: Mar 28, 2024, 4:00 PM
28.24
+0.73 (2.65%)
After-hours: Mar 28, 2024, 5:38 PM EDT

Intellia Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 202320222021202020192018201720162015
Revenue
36.2852.1233.0557.9943.130.4326.1216.486.04
Revenue Growth (YoY)
-30.40%57.69%-43.01%34.55%41.63%16.53%58.49%172.65%-
Gross Profit
36.2852.1233.0557.9943.130.4326.1216.486.04
Selling, General & Admin
116.590.3171.144.1741.0632.1928.0316.88.28
Research & Development
435.07419.98229.81150.41108.4189.1267.6531.8411.17
Operating Expenses
551.57510.29300.9194.58149.47121.395.6748.6419.45
Operating Income
-515.29-458.16-267.85-136.58-106.37-90.87-69.56-32.16-13.41
Other Expense / Income
-34.116.020.04-2.35-6.84-5.53-2.01-0.53-
Pretax Income
-481.19-474.19-267.89-134.23-99.53-85.34-67.54-31.63-13.41
Income Tax
00000000-1.01
Net Income
-481.19-474.19-267.89-134.23-99.53-85.34-67.54-31.63-12.4
Shares Outstanding (Basic)
89777156474336220
Shares Outstanding (Diluted)
89777156474336220
Shares Change
15.33%8.57%26.63%18.50%9.70%19.62%62.03%9044.86%-
EPS (Basic)
-5.42-6.16-3.78-2.40-2.11-1.98-1.88-1.42-51.02
EPS (Diluted)
-5.42-6.16-3.78-2.40-2.11-1.98-1.88-1.42-51.02
Free Cash Flow
-408.07-346.7-237.79-53.5-110.03-67.48-75.3729.94-4.32
Free Cash Flow Per Share
-4.60-4.50-3.35-0.96-2.33-1.57-2.091.35-17.77
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-1420.51%-879.04%-810.37%-235.51%-246.78%-298.58%-266.32%-195.15%-221.86%
Profit Margin
-1326.51%-909.78%-810.49%-231.46%-230.92%-280.42%-258.62%-191.97%-205.11%
Free Cash Flow Margin
-1124.94%-665.17%-719.41%-92.25%-255.28%-221.74%-288.57%181.71%-71.43%
EBITDA
-472.22-466.61-261-127.92-93.95-80.88-64.55-30.53-13.08
EBITDA Margin
-1301.77%-895.25%-789.64%-220.57%-217.96%-265.75%-247.15%-185.27%-216.43%
Depreciation & Amortization
8.987.576.896.315.594.462.991.10.33
EBIT
-481.19-474.19-267.89-134.23-99.53-85.34-67.54-31.63-13.41
EBIT Margin
-1326.51%-909.78%-810.49%-231.46%-230.92%-280.42%-258.62%-191.97%-221.86%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).